Capital Rx is now Judi Rx, maintaining a transparent pass-through PBM model while aligning brand architecture with the Judi ...

Ambient-stable microneedle patches are positioned as a route to reduce refrigeration dependence and simplify administration ...

Symptom-based liver enzyme and triglyceride testing is proposed for isotretinoin patients without risk factors to reduce ...

There will be a greater focus on surgical topics at the 2025 meeting of the American Society of Retina Specialists, compared with previous years, which reflects the need for balan ...

Mike Badome is chief actuary of Arcadia, an outcomes company that helps healthcare organizations improve cost, quality and operational performance.

Preclinical evidence positions ammonia-mediated intestinal barrier disruption as a proximal driver of MASH via gut-derived toxin influx and downstream immune activation, including hyperactive CD8+ T ...

Delinking PBM/GPO fees from list prices targets rebate-driven inflation that raises coinsurance and copays tied to inflated insulin list prices. Mandatory point-of-sale rebate pass-through and ...

Specific brainstem inhibitory neurons help the brain filter out distractions by suppressing competing sensory signals, allowing mice (and presumably humans) to stay focused. Two researchers from Johns ...

FDA authorization positions enlicitide as the first oral PCSK9 inhibitor, targeting PCSK9–LDLR interaction via macrocyclic peptide binding to deliver substantial LDL-C lowering in a daily pill ...

Bevacizumab reached 29.8% of 2025 injections, rising from 23.3% in 2024, while aflibercept 2 mg fell to 21.9% from 36.9% in 2024. Reduced Good Days copay assistance disrupted affordability for branded ...